PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commerc ...

Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. "Itovebi is the first treatment ...

Core Viewpoint - Pharvaris N.V. has announced the pricing of an underwritten offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 ordinary shares at $19.99 each, aiming to raise approximately $175 million before expenses [1]. Group 1: Offering Details - The offering includes 8,250,000 ordinary shares priced at $20.00 each and pre-funded warrants for 500,000 shares at $19.99 each, with the total gross proceeds expected to be around $175 million [1]. - Pharvaris has granted underwriters a 30-day option to purchase an additional 1,312,500 ordinary shares at the public offering price [1]. - The offering is expected to close on or about July 24, 2025, subject to customary closing conditions [1]. Group 2: Company Background - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases, including hereditary angioedema (HAE) [5]. - The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for preventing and treating angioedema attacks [5]. - Pharvaris is currently conducting pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks [5]. Group 3: Underwriters - Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are acting as joint book-running managers for the offering [2]. - The shares and pre-funded warrants are being offered under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [2].

Core Viewpoint - XORTX Therapeutics Inc. has successfully closed a non-brokered private placement, raising US$925,000 through the issuance of 1,267,123 units at a price of US$0.73 per unit, aimed at funding its gout and kidney disease programs [1][3]. Group 1: Offering Details - Each unit issued consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of an additional common share at US$1.20 for a period of 60 months [2]. - If the closing price of the common shares exceeds US$2.00 for ten consecutive trading days, the warrants will be accelerated and will expire 30 business days after notice [2]. - The offering was approved by the TSX Venture Exchange, and the securities issued will not be subject to a statutory hold period [3]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for gout programs, general corporate purposes, and working capital [3]. Group 3: Related Party Transactions - The issuance of 8,191 units to an insider constitutes a related party transaction, with exemptions from formal valuation and minority shareholder approval requirements due to the transaction's value being below 25% of the company's market capitalization [5]. Group 4: Company Overview - XORTX Therapeutics is focused on developing therapies for gout and progressive kidney disease, with three advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [7]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism to reduce uric acid production [7].

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired: (a) Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, ...

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to pre ...

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pha ...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today that it intends to offer and sell $150,000,000 of ordinary shares in an underwritten public offering. All shares in the offeri ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a plac ...

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, i ...